2025-06-15-花旗集团-吉利德科学公司（GILD）_吉利德科学公司（GILD.O）_首席执行官_首席财务官电话会议系列_吉利德讨论中的五大要点_11页_261kb

Gilead Sciences (GILD) Analyst Commentary Summary

• Policy & Strategy: Gilead remains committed to R&D and advocates for PBM reform. Plans to pursue large acquisitions, focusing on I&I and oncology. Preparing for potential delays due to clinical holds on novel programs.
• Portfolio Growth:
  • Lenacapavir (Len for PrEP): Launch expected to improve adherence and expand access. Three phases: convert existing users, reach non-users, expand globally. Significant cost-saving potential via reduced HIV diagnoses.
  • Anito-cel: High efficacy (97% ORR, 68% CR) in 4L+ multiple myeloma with no delayed neurotoxicity. Expected 2024 launch, addressing unmet need. Potential for surrogate endpoint approval.
  • Trodelvy: Expected expansion into first-line TNBC, driving oncology growth.
• Commentary Highlights:
  • Tariffs: Relatively low exposure due to US-based IP and ability to absorb non-sector tariffs, supported by strong financial position.
  • Medicare/Medicaid: PrEP market is largely commercial; potential Medicaid changes are unlikely to impact HIV treatment business.
• Valuation: DCF model target price $125, based on strong free cash flow projections and 8% WACC. 13.7% expected share price return, 2.7% dividend yield, 16.4% expected total return. Market Cap stands at ~$136.9B.
• Key Risks: Competitive pressures in HIV, clinical pipeline disappointments, slower HIV PrEP market growth (e.g., Lenacapavir), weaker launch performance (e.g., Livdelzi).
• Actions: Maintain "Buy" rating.